

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/616,210	07/08/2003	Michael S. Kopreski	00-1313-D	9776
7590 09/23/2005			EXAMINER	
McDonnell Bo	ehnen Hulbert & Bergl	LU, FRANK WEI MIN		
32nd Floor 300 S. Wacker Drive			ART UNIT	PAPER NUMBER
Chicago, IL 60606			1634	
			DATE MAILED: 09/23/200	5

Please find below and/or attached an Office communication concerning this application or proceeding.

l	Application No.	Applicant(s)				
Office Astice Comment	10/616,210	KOPRESKI ET AL.				
Office Action Summary	Examiner	Art Unit				
	Frank W. Lu	1634				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPL' WHICHEVER IS LONGER, FROM THE MAILING D Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMU 36(a). In no event, however, may will apply and will expire SIX (6) No. c, cause the application to become	NICATION.  y a reply be timely filed  MONTHS from the mailing date of this communication.  BABANDONED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>1-28</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) 1-28 are subject to restriction and/or election requirement.						
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)						
) Notice of Draftsperson's Patent Drawing Review (PTO-948)  Paper No(s)/Mail Date  Notice of Informal Patent Application (PTO-152)						
<ol> <li>Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)</li> <li>Paper No(s)/Mail Date</li> </ol>	6)  Other:	• • • • • • • • • • • • • • • • • • • •				

U.S. Patent and Trademark Office PTOL-326 (Rev. 7-05) Art Unit: 1634

## **DETAILED ACTION**

## Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - Claims 1 and 2, drawn to a diagnostic kit, classified in class 536, subclasses 24.3
     and 24.33.
  - II. Claims 3-17, drawn to a method of detecting 5T4 RNA in blood plasma or serum in blood plasma or serum from a human (claims 3, 5, 6, and 12-14) and a method of detecting 5T4 RNA in a bodily fluid from a human (claims 4-6 and 12-14), a method of identifying a human having 5T4 expressing cells or tissue (claims 7-11), and a method for selecting a human with cancer for a 514 directed therapy (claims 15-17), classified in class 435, subclass 91.51.
  - III. Claims 18-28, drawn to a method of detecting 5T4 RNA in blood plasma or serum from a woman for detecting, monitoring, or evaluating trophoblast tissue (claims 18-20), a method of detecting trophoblast tissue in a woman post-partum or with an antecedent pregnancy (claims 21-23), and a method of monitoring the placenta during a pregnancy, classified in class 435, subclass 91.51.
- 2. The inventions are distinct, each from the other because of the following reasons:

Groups I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the product as claimed can be used in a materially different

Application/Control Number: 10/616,210

Art Unit: 1634

process of using that product such as making an array comprising primers or probes recited in claim 1.

Groups I and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the product as claimed can be used in a materially different process of using that product such as making an array comprising primers or probes recited in claim 1.

Groups II and III are distinct and independent inventions in that they are directed to different methods which have different modes of operation, different functions, or different effects. As a result, different and distinct searches will have to be performed. For example, the search required for Group II such as 5T4 directed therapy in claim 15 is not required for Group III while the search required for Group III such as placenta in claim 24 is not required for Group III.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the

Art Unit: 1634

application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

3. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993)(See 37 CAR § 1.6(d)). The CM Fax Center number is (571)273-8300.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Frank Lu, Ph.D., whose telephone number is (571)272-0746. The examiner can normally be reached on Monday-Friday from 9 A.M. to 5 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W. Gary Jones, can be reached on (571)272-0745.

Any inquiry of a general nature or relating to the status of this application should be directed to the Chemical Matrix receptionist whose telephone number is (703) 308-0196.

Frank Lu PSA

September 15, 2005

FRANKLU
PATENT EXAMINER

Muleur